ClinicalTrials.gg
CompletedNCT00096473Updated Apr 1, 2011

Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease

A Phase 3 interventional study of Donepezil hydrochloride in Alzheimer's Disease and Dementia, sponsored by Eisai Inc.. Completed at 42 sites in 6 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-04-01.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
229
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
10th of 58
229 · median 79
Started
2001
the only one that year
Phase 3
10 of 60
1 open now
Registered
2nd of 60
by date
Lead sponsor
9 of 60
Eisai Inc.

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 10th largest by enrollment of the 58 interventional ones that give a count, is the only one that started in 2001, is one of 10 in phase 3, and was the 2nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimer's disease.

Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person's memory to work better.

03

Conditions studied

  • Alzheimer's Disease
  • Dementia

Keywords

  • Alzheimer's Disease
  • dementia
  • acetylcholinesterase
  • donepezil
  • Aricept
  • memory loss
  • Severe dementia of the Alzheimer's type
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically diagnosed Alzheimer's Disease with score 1\~12
  • Have not been treated by any medication for Alzheimer's Disease in past 3 months
  • Live in community or Assisted Living Facility
  • Healthy or with chronic diseases that are medically controlled or stabilized
  • Able to swallow tablets

Exclusion criteria

Exclusion Criteria:

  • Any primary neurological or psychiatric diagnosis (including depressive disorder) other than Alzheimer's Disease
  • Dementia caused by organic diseases other than Alzheimer's Disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
229 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Assessments of global and cognitive function of Severe AD patients

Secondary outcomes

  1. Assessment of behavior and performance on Activity of Daily Living in severe AD patients

  2. Assessment of caregiver burden

07

Study locations

42 sites
  • Northport, Alabama, United States
  • Phoenix, Arizona, United States
  • Sun City, Arizona, United States
  • Tucson, Arizona, United States
  • San Francisco, California, United States
  • Santa Monica, California, United States
  • Torrance, California, United States
  • Denver, Colorado, United States
  • Ft. Lauderdale, Florida, United States
  • Ft. Myers, Florida, United States
  • North Miami, Florida, United States
  • St. Petersburg, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • New Orleans, Louisiana, United States
  • Springfield, Massachusetts, United States
  • Long Branch, New Jersey, United States
  • Piscataway, New Jersey, United States
  • New Hyde Park, New York, United States
  • Greenville, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Centerville, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Medford, Oregon, United States
  • Portland, Oregon, United States
  • Jenkintown, Pennsylvania, United States
  • Austin, Texas, United States
  • Houston, Texas, United States
  • Randwick, New South Wales, Australia
  • Brisbane, Queensland, Australia
  • Woodville South, South Australia, Australia
  • Heidelberg West, Victoria, Australia
  • Nedlands, Western Australia, Australia
  • Toronto, Ontario, Canada
  • Hôpital Broca-La Rochefoucauld
    Paris, France
  • Belfast, Ireland
  • St. Leonards on Sea, East Sussex, United Kingdom
  • West End, Southampton, United Kingdom
  • Swindon, Wilshire, United Kingdom
  • Bath, United Kingdom
  • Blackpool, United Kingdom
  • Bradford, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2001, a primary completion of Jun 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2004
First posted
Nov 10, 2004
Start
Jan 2001
Primary completionActual
Jun 2005
CompletionActual
Sep 2005
Last update
Apr 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00096473
Lead sponsor
Eisai Inc.
Collaborators
Pfizer
First posted
Nov 10, 2004
Start date
Jan 2001
Primary completion
Jun 2005
Completion
Sep 2005
Last update
Apr 1, 2011

Study contacts

Sharon Richardson, Ph.D.
study director · Eisai Inc.
Honglan Li, Ph.D.
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion